

# Sabrina Pagano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993102/publications.pdf>

Version: 2024-02-01

50  
papers

1,009  
citations

430874

18  
h-index

454955

30  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1195  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. <i>Lancet Rheumatology</i> , The, 2022, 4, e11-e13.	3.9	31
2	Bariatric Surgery Leads to a Reduction in Antibodies to Apolipoprotein A-1: a Prospective Cohort Study. <i>Obesity Surgery</i> , 2022, 32, 355-364.	2.1	3
3	Role of Clinical Characteristics and Biomarkers at Admission to Predict One-Year Mortality in Elderly Patients with Pneumonia. <i>Journal of Clinical Medicine</i> , 2022, 11, 105.	2.4	6
4	Kinetics of inflammatory biomarkers to predict one-year mortality in older patients hospitalized for pneumonia: a multivariable analysis. <i>International Journal of Infectious Diseases</i> , 2022, 122, 63-69.	3.3	0
5	Autoantibodies against apolipoprotein A1 after COVID-19 predict symptoms persistence. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	3.4	12
6	Anti-ApoA1 IgGs predict resistance to waist circumference reduction after Mediterranean diet. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13410.	3.4	2
7	SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A1. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13661.	3.4	10
8	Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A1?. <i>European Journal of Clinical Investigation</i> , 2021, 52, e13713.	3.4	3
9	Atherosclerotic plaque vulnerability is increased in mouse model of lupus. <i>Scientific Reports</i> , 2020, 10, 18324.	3.3	8
10	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. <i>PLoS ONE</i> , 2020, 15, e0238089.	2.5	71
11	Antiapolipoprotein A-1 Autoantibody Positivity Is Associated with Threatened Abortion. <i>BioMed Research International</i> , 2020, 2020, 1-8.	1.9	0
12	Prognostic and therapeutic considerations of antibodies against carrier apolipoprotein A1 in the general population. <i>Clinical and Translational Immunology</i> , 2020, 9, e1220.	3.8	6
13	Auto-antibodies against apolipoprotein A-1 block cancer cells proliferation and induce apoptosis. <i>Oncotarget</i> , 2020, 11, 4266-4280.	1.8	0
14	Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 59, 534-544.	1.9	3
15	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1002.	2.4	11
16	Autoantibodies to Apolipoprotein A-1 as Independent Predictors of Cardiovascular Mortality in Renal Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2019, 8, 948.	2.4	10
17	Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against Apolipoprotein A-1 in Obese and Healthy Subjects. <i>Journal of Clinical Medicine</i> , 2019, 8, 1225.	2.4	13
18	Deficiency of Monoacylglycerol Lipase Enhances IgM Plasma Levels and Limits Atherogenesis in a CB2-Dependent Manner. <i>Thrombosis and Haemostasis</i> , 2019, 119, 348-351.	3.4	9

#	ARTICLE	IF	CITATIONS
19	Association of novel biomarkers with major clinical outcomes in a cohort of patients with atherosclerotic renovascular disease. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 488-501.	1.6	0
20	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. <i>Atherosclerosis</i> , 2019, 284, 253-259.	0.8	9
21	ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. <i>Journal of Immunological Methods</i> , 2019, 469, 33-41.	1.4	5
22	Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 732.	4.1	11
23	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. <i>Journal of Clinical Medicine</i> , 2019, 8, 2035.	2.4	10
24	Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3128-3146.	1.9	10
25	C-Terminus apoA-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formation. <i>Journal of Clinical and Molecular Medicine</i> , 2019, 2, .	0.4	1
26	Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. <i>Hepatology International</i> , 2018, 12, 17-25.	4.2	11
27	Infection-Induced Humoral Autoimmunity. <i>Journal of the American College of Cardiology</i> , 2018, 72, 955-956.	2.8	0
28	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. <i>Journal of Infection</i> , 2018, 76, 186-195.	3.3	12
29	Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 2342-2349.	2.4	27
30	Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms. <i>Frontiers in Immunology</i> , 2017, 8, 437.	4.8	30
31	Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. <i>Thrombosis and Haemostasis</i> , 2016, 116, 764-771.	3.4	35
32	Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 554-564.	3.4	20
33	Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. <i>Vascular Pharmacology</i> , 2016, 85, 57-65.	2.1	20
34	The Associations of Blood Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin with Progression from CKD to ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2141-2149.	4.5	39
35	CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. <i>Endocrinology</i> , 2015, 156, 4707-4719.	2.8	20
36	The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?. <i>PLoS ONE</i> , 2015, 10, e0132780.	2.5	26

#	ARTICLE	IF	CITATIONS
37	Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. <i>Thrombosis and Haemostasis</i> , 2015, 114, 410-422.	3.4	36
38	Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice. <i>Vascular Pharmacology</i> , 2015, 71, 84-92.	2.1	7
39	Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2015, 45, 369-379.	3.4	10
40	18FDG-PET-CT. <i>Stroke</i> , 2014, 45, 3561-3566.	2.0	27
41	Definition of Human Apolipoprotein A-I Epitopes Recognized by Autoantibodies Present in Patients with Cardiovascular Diseases. <i>Journal of Biological Chemistry</i> , 2014, 289, 28249-28259.	3.4	26
42	A9.11...Anti-apolipoprotein A1 autoantibodies induce tissue factor activity and expression: a role in atherothrombosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A96.1-A96.	0.9	0
43	Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. <i>Thrombosis and Haemostasis</i> , 2013, 109, 706-715.	3.4	48
44	Anti-Apolipoprotein A-1 IgG Levels Predict Coronary Artery Calcification in Obese but Otherwise Healthy Individuals. <i>Mediators of Inflammation</i> , 2012, 2012, 1-10.	3.0	18
45	Antiapolipoprotein A-1 IgG Chronotropic Effects Require Nongenomic Action of Aldosterone on L-Type Calcium Channels. <i>Endocrinology</i> , 2012, 153, 1269-1278.	2.8	18
46	High Prevalence of Anti-Apolipoprotein/A1 Autoantibodies in Maintenance Hemodialysis and Association With Dialysis Vintage. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 588-594.	0.9	21
47	Evaluation of cardiovascular risk in patients with rheumatoid arthritis: Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?. <i>Arthritis Care and Research</i> , 2012, 64, 817-825.	3.4	38
48	Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. <i>European Heart Journal</i> , 2011, 32, 412-421.	2.2	110
49	Anti-apolipoprotein A1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2640-2650.	6.7	90
50	Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 815-823.	2.2	76